While the individual active ingredients (semaglutide, tirzepatide) are FDA-approved drugs, compounded formulations are customized for individual patients and are not FDA-approved as finished productsthis is standard practice in precision medicine
Therefore, bariatric surgery and GLP-1 receptor agonists should be viewed as potentially complementary obesity-treatment options rather than competing pathways
The overall market size is expected to grow by 8X during the same period, supported by expanding treatment eligibility, increasing public reimbursement coverage, and growing clinical evidence for cardiovascular risk reduction benefits
It was approved in 2019 for diabetes management
Warnings: Consult a healthcare professional before using this product if you are trying to conceive, pregnant, or lactating, under the age of 18, or have a medical condition
Semaglutide is well supported by trials for weight management